Status:
UNKNOWN
Laparoscopic Assisted Transanal Total Mesorectal Excision for Rectal Cancer in Low Site
Lead Sponsor:
Beijing Friendship Hospital
Collaborating Sponsors:
Peking Union Medical College Hospital
Peking University People's Hospital
Conditions:
Rectal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
At present, surgical resection is still the main treatment for the potential cure of rectal cancer. Total mesorectal excision (TME) is the gold standard. The traditional laparoscopic or open surgery f...
Eligibility Criteria
Inclusion
- adenocarcinoma of the rectum by biopsy
- the lower edge of the tumor from the anal margin less than 10cm according to MRI or rigid endoscopy
- tumor diameter less than 4cm
- baseline clinical stage I-III: cT1-3 N0-2 M0 (AJCC v7)
- tolerable to surgery
- be able to understand and willing to participate in this trial with signature
Exclusion
- history of malignant colorectal neoplasia
- recent diagnosis with other malignancies
- patients requiring emergency surgery such as obstruction，perforation and bleeding
- tumor involving adjacent organs, anal sphincter, or levator ani muscle
- muti-focal colorectal cancer
- preoperative poor anal function, anal stenosis, anal injury, or fecal incontinence
- history of inflammatory bowel disease or familial adenomatous polyposis
- participating in other clinical trails
- can not tolerate the surgery
- history of serious mental illness
- pregnancy or lactating women
- preoperative uncontrolled infection
- the researchers believe the patients should not enrolled in
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03253302
Start Date
October 1 2017
End Date
December 1 2021
Last Update
August 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital
Beijing, Beijing Municipality, China, 100050